BioCryst Pharmaceuticals, Inc

BCRX NASDAQ
BCRX
BioCryst Pharmaceuticals, Inc NASDAQ
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

BCRX financial statements

BioCryst Pharmaceuticals, Inc financial statements, including revenue, expenses, profit, and loss

The total revenue of BCRX for the last quarter is 49.92M USD, and it's 5.86% higher compared to the previous quarter. The net income of Q1 22 is -74.20M USD.

TTM
Gross profit
Total revenue
Cost of goods sold
Operating expenses (excl. COGS)
Operating income
Non-operating income, total
Pretax income
Equity in earnings
Taxes
Non-controlling/minority interest
After tax other income/expense
Net income before discontinued operations
Discontinued operations
Net income
Dilution adjustment
Preferred dividends
Diluted net income available to common stockholders
Basic earnings per share (Basic EPS)
Diluted earnings per share (Diluted EPS)
Average basic shares outstanding
Diluted shares outstanding
EBITDA
EBIT
Total operating expenses